Claim Listing

Claim 1 (canceled)

2. **(previously presented)** A pharmaceutical composition, wherein:

the composition comprises one or more orally deliverable dose units, each comprising a selective cyclooxygenase-2 inhibitory drug of low water solubility in a therapeutically effective amount, wherein the drug is present in solid particles having a weight average particle size of about 500 nm to about 900 nm;

the selective cyclooxygenase-2 inhibitory drug is a compound of formula:



;

R^3 is methyl or amino;

R^4 is hydrogen, C_{1-4} alkyl, or C_{1-4} alkoxy;

X is N or CR^5;

R^5 is hydrogen or halogen; and

Y and Z are independently carbon or nitrogen atoms defining adjacent atoms of a five- to six-membered ring that is unsubstituted or substituted at one or more positions with oxo, halo, methyl, or halomethyl.

Claim 3 (canceled).

4. **(previously presented)** The composition of Claim 2 wherein the dose units are in the form of discrete solid articles.

5. **(original)** The composition of Claim 4 wherein the solid particles are tablets or capsules.

6. **(previously presented)** The composition of Claim 2 that is in the form of a substantially homogeneous flowable mass from which single dose units are measurably removable.

7. **(original)** The composition of Claim 6 wherein the substantially homogeneous flowable mass is a liquid suspension.

Claims 8-11 (canceled)

12. **(previously presented)** The composition of Claim 2 wherein Y and Z are independently carbon or nitrogen atoms defining adjacent atoms of a ring selected from the group consisting of cyclopentenone, furanone, methylpyrazole, isoxazole, and pyridine rings substituted at no more than one position.

13. **(previously presented)** The composition of Claim 2 wherein the selective cyclooxygenase-2 inhibitory drug is selected from the group consisting of celecoxib, deracoxib, valdecoxib, rofecoxib, 5-chloro-3-(4-methylsulfonyl)phenyl-2-(2-methyl-5-pyridinyl)pyridine, 2-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-2-cyclopenten-l-one and (S)-6,8-dichloro-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid.

14. **(original)** The composition of Claim 13 wherein the selective cyclooxygenase-2 inhibitory drug is celecoxib.

15. **(original)** The composition of Claim 14 comprising about 10 mg to about 1000 mg celecoxib in each dose unit.

Claims 16-18 (canceled)

19. **(previously presented)** A method of treating a medical condition or disorder in a subject where treatment with a cyclooxygenase-2 inhibitor is indicated, wherein:

the method comprises orally administering one or more dose units of a composition one to about six times a day;

the composition comprises a selective cyclooxygenase-2 inhibitory drug of low water solubility in a therapeutically effective amount, wherein the drug is present in solid particles having a weight average particle size of about 500 nm to about 900 nm;

the selective cyclooxygenase-2 inhibitory drug is a compound of formula:



;

R^3 is methyl or amino;

R^4 is hydrogen, C_{1-4} alkyl, or C_{1-4} alkoxy;

X is N or CR^5;

R^5 is hydrogen or halogen; and

Y and Z are independently carbon or nitrogen atoms defining adjacent atoms of a five- to six-membered ring that is unsubstituted or substituted at one or more positions with oxo, halo, methyl, or halomethyl.

20. **(previously presented)** The method of Claim 19 wherein the medical condition or disorder is accompanied by acute pain.

21. **(previously presented)** The method of Claim 19 wherein the dose units are in the form of discrete solid articles.

22. **(previously presented)** The method of Claim 21 wherein the solid articles are tablets or capsules.

23. **(previously presented)** The method of Claim 19 that is in the form of a substantially homogeneous flowable mass from which single dose units are measurably removable.

24. **(previously presented)** The method of Claim 19 wherein Y and Z are independently carbon or nitrogen atoms defining adjacent atoms of a ring selected from the group consisting of cyclopentenone, furanone, methylpyrazole, isoxazole, and pyridine rings substituted at no more than one position.

25. **(previously presented)** The method of Claim 19 wherein the selective cyclooxygenase-2 inhibitory drug is selected from the group consisting of celecoxib, deracoxib, valdecoxib, rofecoxib, 5-chloro-3-(4-methylsulfonyl)phenyl-2-(2-methyl-5-pyridinyl)pyridine, 2-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-2-cyclopenten-1-one and (S)-6,8-dichloro-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid.

26. **(previously presented)** A method of making a medicament useful in treatment or prophylaxis of a COX-2 mediated condition or disorder, wherein:

the method comprises incorporation of a selective cyclooxygenase-2 inhibitory drug of low water solubility into a pharmaceutical composition comprising one or more orally deliverable dose units, wherein the drug is in the form of solid particles having a weight average particle size of about 500 nm to about 900 nm;

the selective cyclooxygenase-2 inhibitory drug is a compound of formula:



;

R^3 is methyl or amino;

R^4 is hydrogen, C_{1-4} alkyl, or C_{1-4} alkoxy;

X is N or CR^5;

R^5 is hydrogen or halogen; and

Y and Z are independently carbon or nitrogen atoms defining adjacent atoms of a five- to six-membered ring that is unsubstituted or substituted at one or more positions with oxo, halo, methyl, or halomethyl.

27. **(previously presented)** The method of Claim 26 wherein the dose units are in the form of discrete solid articles.

28. **(previously presented)** The method of Claim 27 wherein the solid articles are tablets or capsules

29. **(previously presented)** The method of Claim 25 that is in the form of a substantially homogeneous flowable mass from which single dose units are measurably removable.

30. **(previously presented)** The method of Claim 25 wherein Y and Z are independently carbon or nitrogen atoms defining adjacent atoms of a ring selected from the group consisting of cyclopentenone, furanone, methylpyrazole, isoxazole, and pyridine rings substituted at no more than one position..

31. **(previously presented)** The method of Claim 25 wherein the selective cyclooxygenase-2 inhibitory drug is selected from the group consisting of celecoxib, deracoxib, valdecoxib, rofecoxib, 5-chloro-3-(4-methylsulfonyl)phenyl-2-(2-methyl-5-pyridinyl)pyridine, 2-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-2-cyclopenten-1-one and (S)-6,8-dichloro-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid.